Monday, 30 January 2017

Robotic Rehabilitation and Assistive Technologies Market Forecasts up to 2024, Research Reports

The robotic rehabilitation and assistive technologies market accounts for rehabilitation robots and assistive technology robots. A robot is a mechanical and virtual intelligent agent that is guided by a computer program. A robot is an electromechanical machine which performs a task automatically or guided by a remote control. Robotics is the branch of technology which deals with the design, construction, operation and application of robots, while the field of research devoted to extending rehabilitation through the implementation of robotic devices is called Rehabilitation Robotics. A rehabilitation robot guides movement of a disabled person or elderly person with the intention of improving sensorimotor functions like arm, hand, leg and ankle. An assistive robot performs a task for the benefit of an elderly person or a patient with disability. These robotic devices are helpful for millions of people who desire to conquer the disability.
Robotic Rehabilitation and Assistive Technologies Market Segmentation
The global market for robotic rehabilitation and assistive technologies, on the basis of product type, has been segmented into assistive robots, prosthetics, orthotics, therapeutic robots and exoskeleton robotic systems. The global market for robotic rehabilitation and assistive technologies is also segmented as fixed base robots and mobile robots. Fixed based robots can be placed nearby a patient for medication, feeding and other tasks. Mobile robots can be used for mobility support and for fetching or carrying. During the forecast period from 2016 to 2024, worldwide market is poised to achieve significant growth as a result of growing application of robotic devices across the rehabilitation centers and healthcare facilities offering rehabilitation to patients suffering from physical disabilities such as spinal cord injury, cerebral palsy, rheumatoid arthritis and stroke.
Robotic Rehabilitation and Assistive Technologies Market Drivers
Worldwide increasing elderly population along with growing prevalence of conditions such as spinal cord injury, cerebral palsy, rheumatoid arthritis, dementia and other age-related disabilities are playing a key role in driving the global market for robotic rehabilitation and assistive technologies. According to the Centers for Disease Control and Prevention, approximately 200,000 people are living with spinal cord injury in the U.S. and the annual incidence has been estimated at 15 to 40 new cases per million population, nearly 12,000 to 20,000 new cases in a year. The Centers for Disease Control and Prevention stated in November 2013 that approximately 52.5 million U.S. adults suffer from arthritis, nearly 23% of the total adult population. According to a U.S. based website called MyChild at CerebralPalsy.org, around 764,000 children and adults have cerebral palsy in the U.S. Of which, nearly 500,000 are aged below 18 years. Globally, the prevalence of dementia was estimated around 35.6 million in 2010 that is expected to reach approximately 65.7 million by 2030 and nearly 115.4 million in 2050. More than 50% of all people with dementia lived in developing and poor economy countries in 2010 which is expected to exceed 60% by the end of 2030. Such high prevalence of conditions is expected to drive the demand for rehabilitation robots and assistive robots across rehabilitation centers, hospitals and other healthcare centers. High cost of robotic devices is one of the major factors that is restraining the market growth, especially in countries with low and medium economy.
In terms of geography, the global robotic rehabilitation and assistive technologies market has been categorized into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). North America and Europe represented the first and second largest markets for robotic rehabilitation and assistive technologies in 2013. It was mainly due to well established healthcare infrastructure of these regions.
Robotic Rehabilitation and Assistive Technologies Market Key Players
Intuitive Surgical Inc., Accuray, Inc., Mazor Robotics Ltd. and Health Robotics S.R.L. are some major players of this market.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
at No comments:

Alpha Mannosidosis Market is expected to progress at a CAGR of 11.9% between 2017 and 2024

Global Alpha Mannosidosis Market: Snapshot
Alpha mannosidosis is an inherited medical condition tissues and organs of the human body to function in abnormal ways. The commonly seen dysfunctions in patients suffering from this disease are distinctive facial features, intellectual disability, and skeletal abnormalities. Some of the other facial features seen amongst patients are a protruding forehead, large head, rounded eyebrows, low hairline, outsized ears, expanded jaw, flattened bridge of the nose, overgrown gums, widely spaced teeth, and outsized tongue. Though this is a rare disease, a definite rise in the population has increased the number of patients thereby augmented the demand for drugs required for treating alpha mannosidosis.
Owing to this reason, the opportunity in the global market is expected to be worth US$21.8 mn by the end of 2024 as against US$2.6 mn in 2015, as the market progresses at a CAGR of 11.9% between 2017 and 2024. The global market for alpha mannosidosis is being driven factors such as market exclusivity being enjoyed by orphan drugs, fee reductions, tax credits, increasing investment in the rare disease treatment, and premium pricing.
BMT Emerges as Leading Therapy for Treating Alpha Mannosidosis
Statistics show that alpha mannosidosis affects one in every 10, 00,000 people across the globe. The two types of treatment available for treating this disease are bone marrow transplant (BMT) and enzyme replacement therapy (ERT). Currently, bone marrow transplant (BMT) is the most popularly used treatment for patients. However, ERT is also picking up pace as the manufacturers operating in the segment are vying for commercial roll out of therapies. A promising therapy for lysosomal storage diseases (which are similar to alpha mannosidosis) is an enzyme replacement therapy (ERT). The therapy introduces the missing enzyme in the patient’s blood stream, which is absorbed by the cells then delivered to the lysosomes.
Asia Pacific and North America Show Promise of Steady Growth during Forecast Period
Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Asia Pacific is projected to hold a dominant share in the market in 2017. This dominance will be attributable to the growing awareness about the disease in developing countries. Presently, the Government of Australia has implemented a national plan for helping patients with rare diseases to reduce the mortality rate due to these diseases. The plan aims to raise awareness about the burden of rare diseases among patients, its impact on social life, and healthcare professionals.
North America alpha mannosidosis market is also expected to witness a remarkable growth rate in the coming years. The orphan drug law will boost the new drug discovery efforts as it aims to offer monetary as well as non-financial benefits to manufacturers. The biggest incentive offered North America is a 50% cut the cost incurred for conducting clinical trials, seven years of market exclusivity for orphan drugs, eligibility for federal research grants, and waiver of user fees.
The leading players operating in the global alpha mannosidosis market is Zymenex. The company currently focusses on research and development of biologics that are designed to fight rare and life-threatening genetic diseases. The company has developed recombinant enzyme indicated for patients with alpha mannosidosis, which is known as Lamazym (velmanase alfa) in the market.
at No comments:

Dental Consumables Market - Latest Innovations, Drivers, Restraints, Challenges and Forecast 2016 - 2024

Global Dental Consumables Market: Snapshot
The growing number of dental issues across the world are fuelling the demand for dental consumables. These consumables are predominantly used for tooth restoration, treating dental impairments, and related gingival tissues. The global dental consumables market has been thriving in recent years due to the increasing dental tourism in developing countries. Citing these reasons, analysts predict that global dental consumables market will be worth US$33.4 bn by the end of 2024 from US$19.6 bn in 2015. The overall market between 2016 and 2024 is expected to rise at a CAGR of 6.1%.
Several emerging economies such as Turkey, Hungary, and India are expected to offer lucrative opportunities to the global market in the coming years. The low cost of labor, less government intervention, effective dental treatments, and improving services are expected to draw in a large number of patients for dental treatments. The market is also thriving due to the remarkable improvements in the quality of dental implants, which has assured several patients to opt for dental treatments. Rising disposable incomes, improving lifestyles, and growing awareness about oral healthcare are also expected to drive the global dental consumables market in the next few years.
Resemblance of Crowns and Bridges to Natural Teeth Make them Most Preferred Choice of Dental Consumables
In terms of products, the global market is segmented into retail dental care essentials, crowns and bridges, dental biomaterials, orthodontics, dental implants, dental consumables, endodontics, and periodontics. Of these, the crowns and bridges segment has been leading the global market and is expected to remain dominant all throughout the forecast period. These devices are used for creating a protective layer over damaged part of the tooth. The segment is receiving a significant boost due to introduction of advanced technologies such as CAM and CAD. Analysts anticipate that the market could also benefit from the rising awareness about cosmetic dentistry, improving life expectancy, and a huge pool of geriatrics across the globe. The report also suggest that stability of crowns and bridges and their resemblance to natural-looking tooth are also expected to drive the demand for this segment. Furthermore, the rising cost of metals has negatively impacted the metal-based crowns and bridges, tilting the demand toward newer ones.
Improvements in Oral Healthcare across Europe keeps Region in the Lead
In terms of geography, the global dental consumables market is segmented into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa. Europe is the frontrunner in the global market due to the ever-increasing pool of geriatrics. The growing concerns for oral health care are expected to keep Europe growing at a steady CAGR in the global dental consumables market during the forecast period. The growing funding for improving and expanding oral health care facilities across Europe is also expected to benefit this regional market.
On the other hand, Asia Pacific is also expected to show a steady growth rate in the coming years. The emergence of the middle class is the primary growth driver for this regional market. The booming dental tourism in Asia Pacific is estimated to keep up the demand for dental consumables in the coming years. Furthermore, improving disposable incomes, access of oral health care, and growing awareness will also boost the growth of the regional market.
at No comments:

Smart Medical Devices Market Outlook and Forecast up to 2024

Global Smart Medical Devices: Snapshot
Smart medical devices have gained traction in the recent past due to the multitude of benefits they provide to the patient and the caregiver. These devices have radically changed the way a disease is managed, by storing copious amounts of data in a logical format to draw insightful inferences. From understanding patterns of diseases or health issues, smart medical devices have largely helped users to keep an efficient tract of their health and fitness regime. Owing to these reasons, the global smart medical devices market is expected to soar at a CAGR of 7.8% to reach US$66.1 bn by 2024 as compared to US$33.7 bn in 2015.
Convenience of Tracking Health Issues through Smart Medical Devices Bodes Well for Global Market
Smart medical devices are being used as important tools by physicians to detect various disease by monitoring vital signs. Chronic disease such as hypertension and diabetes have thus received a fresh perspective from both the medical industry as well as the patients. From a broader perspective, these devices have drastically reduced the workload for healthcare providers by closely monitoring patient health and taking quick action in case of any major change in the readings. The report predicts that the demand for smart medical devices will be attributable to the growing pool of geriatrics, who are prone to a wide range of illnesses. Furthermore, the rapid technological advancements in the fitness devices have also lured in a large base of consumers who are interested in monitoring their heart rate, calorie intake, and the number of calories burned. The user-friendliness of these devices is also expected to fuel the uptake of smart medical devices in the coming few years.
Diagnostic and Monitoring Devices to Remain Popular as Inclination toward Fitness Increases
The various products available in the smart medical devices market are On the basis of product, the global market is segmented into therapeutic devices, diagnostic and monitoring devices, and injury prevention and rehabilitation devices. Of these, the diagnostic and monitoring devices segment is expected to dominate the global market. Growing awareness toward fitness is expected to drive the uptake of these devices. The quick and easy accessibility to fitness prompts, near-accurate monitoring of health condition such as diabetes and blood pressure, and wide availability of devices in varying price range is expected to work in favor of this segment.
Improving Medical and Healthcare Services in North America Drive Regional Market
In terms of geography, the global smart medical devices market is segmented into North America, Asia Pacific, Europe, the Middle East and Africa, and Latin America. North America is expected to exhibit excellent growth rate in the coming years. The adoption of technology in the region and its acceptability amongst the overall population is estimated to benefit the regional market. The ongoing upgradation of medical and healthcare services in the region have also played a crucial role in swift sales of smart medical devices all across North America.
Some of the leading players operating in the global smart medical devices are Abbott Laboratories, Apple Inc., Dexcom, Inc., Fitbit, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Medtronic plc, NeuroMetrix, Inc., Samsung Electronics Co., Ltd, and Sonova. F. Hoffmann-La Roche Ltd. These players are expected to retain the lead in the coming years due to their penetration in emerging economies and product innovation. The growing investments in the development of sophisticated products are also anticipated to drive the soaring revenues of these players in the coming few years.
at No comments:

Pulmonary Drugs Market: Combination Drugs Remain Favorite amongst Medical Professionals

Global Pulmonary Drugs Market: Snapshot
This report on pulmonary drugs studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pulmonary drugs market with respect to the leading market segments based on major products, key applications, distribution channels, and geographies.
Global Pulmonary Drugs Market: Segmentation
The global pulmonary drugs market has been studied based on major drug classes, application segments, major distribution channels, and regional as well as national markets. Based on drug classes, the global market has been categorized into eight major segments: Inhaled corticosteroids (ICS), long-acting beta2-agonists (LABA), antihistamines, vasodilators, short-acting beta2-agonists (SABA), anticholinergics, combination drugs, and others. Based on application, the global market has been categorized into five segments: Asthma & COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others. Based on distribution channels, the global market has been categorized into four key segments: hospital pharmacies, retail pharmacies, drug stores, and e-commerce.
The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year.
Global Pulmonary Drugs Market: Scope
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global pulmonary drugs market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products/applications/distribution channels/geographies. The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the pulmonary drugs market report. The section also includes competition matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global pulmonary drugs market.
Global Pulmonary Drugs Market: Geographical Outlook
Geographically, the pulmonary drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Each regional market for pulmonary drugs market has been further categorized into major product, application, and end-user segments considered within the scope of the study. Key country (U.S., Japan, Germany, France, U.K., Australia, Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with CAGR % from 2016 to 2024 are provided for all the regions and nations considering 2015 as the base year.
Key Players Mentioned in the Report are:
The report also profiles key players operating in the pulmonary drugs market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include AstraZeneca plc, Novartis AG, F. Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Actelion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals, Inc. and others
at No comments:

Pyrogen Testing Market is expected to surge at a CAGR of 11.9%

Global Pyrogen Testing Market: Snapshot
The global pyrogen testing market has been witnessing a rapid growth rate in recent years as the pharmaceutical, medical devices, and biotechnology industries are undergoing a huge change. The growing support from governments to launch new drugs to fight several new diseases has augmented the demand for pyrogen testing in the past few decades. Pyrogens are known to cause fever and body ache after being injected. This testing method helps in identifying the presence of endotoxin substances and is being extensively used in the development of new drugs. According to the research report, the global pyrogen testing market is expected to be worth US$1,527.8 mn by the end of 2024 as compared to US$570.0 mn in 2015. During the forecast period of 2016 and 2024, the global market is expected to surge at a CAGR of 11.9%.
Investments in Biotechnology and Pharmaceutical Industries Offer Immeasurable Scope for Growth
The emergence of several biotechnology and pharmaceutical companies across the globe is the primary reason for the growth of the global pyrogen testing market. The growing investments in the development of new drugs to improve healthcare is expected to propel the demand for pyrogen testing. Analysts anticipate that the introduction of innovative drugs and launch of biological products with the rise of chronic diseases and favorable government initiatives will support the growth of the global market. The market is also expected to benefit from the rising awareness about chronic conditions, growing expenditure on healthcare, and favorable reimbursement policies.
Despite the steady market drivers, the global market is expected to be restrained by the ongoing efforts to ban on animal tests. The increasing pressure to stop the usage of rabbits for pyrogen testing is likely to be the key restraining factor in the global market. However, the market could stand to profit from the growing medical tourism across Latin America and Asia Pacific. Furthermore, the emergence of the healthcare industry in emerging economies is anticipated to have a positive impact on the overall market during the forecast period.
North America Poised to Dominate Global Market as Healthcare Garners High Interest in the Region
In terms of geography, the global pyrogen testing market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. In 2015, North America held a dominant share of 38.6% in the global pyrogen testing market. This lion’s share was attributable to the strong presence of key players in the region, who are making big investments in research and development. The report projects that the North America market will continue to thrive as healthcare awareness is on the upswing in the region. During the forecast period, the North America pyrogen testing market is expected to expand at a CAGR of 11.6%. The limulus amebocyte lysate test (LAL) test type segment will be popular over others all across North America as it has been until 2015.
The emerging economies of Asia Pacific such as India, China, and Japan are likely to give the overall market a much-needed impetus as well. Owing to this reason, the Asia Pacific pyrogen testing market is likely to expand at a CAGR of 14.3% during the forecast period.
The key players operating in the global pyrogen testing market are Thermo Fisher Scientific, Inc., Genscript, Hyglos Gmbh, Lonza Group, Associates of Cape Cod, Inc., Wako Chemicals USA, Inc., Sanquin and Charles River Laboratories International, Inc., and Merck & Co., Inc.
at No comments:

Clostridium Vaccine (Animal Health) Market is expected to reach US$643.5 mn by 2024

The global clostridium vaccine (animal health) market features a largely consolidated competitive landscape, with the top five companies collectively accounting for a share of over 63% of the overall market in 2015, observes a recent report by Transparency Market Research (TMR). These top vendors, namely Zoetis, Inc., Merck & Co., Sanofi-Aventis, Boehringer Ingelheim, and Eli Lilly and Company hold commanding positions owing to their wide geographic presence and a strong financial backing allowing increased focus on research and development activities.
Top companies in the market aim to strengthen their positions with strategies such as targeted in-licensing, acquisition, and innovative marketing. Use of the digital medium to reach out to an extended consumer base and serve the consumer more effectively has also started becoming a popular strategy. An instance is the recent update made to Bayer’s BCS cowdition smartphone application in July 2016. The enhanced application is expected to help veterinarians to track the current and future hurdles regarding cattle health, which will help minimize the impact of metabolic diseases on dairy cows.
Transparency Market Research estimates that the global clostridium vaccines market will exhibit a healthy 4.9% CAGR over the period between 2016 and 2024. Rising at this rate, the market, which valued at US$418.0 mn in 2015, is expected to reach US$643.5 mn by 2024. In terms of animal species, the swine segment presently leads but is expected to be outpaced by the growth of the ovine segment. In terms of geography, the global market is dominated by North America, which accounted for over 37% of the global market in 2015.
Rising Intervention by Government Bodies to Play Key Role in Market Development
Government initiatives play a key role the development of animal health care markets. For instance, the China market for veterinary healthcare is chiefly driven by compulsory immunization policy, several animal health awareness programs, the easy availability of affordable veterinary vaccines, and fund for research and development in the field. In several other developed as well as developing economies, funds invested by government bodies for the research and development of veterinary vaccines and medications play a key role in boosting the demand for clostridium vaccines.
Along with this, the rising global demand for animal products such as cattle milk, meat, and eggs is also a key factor driving the global market for clostridium vaccines. Animal products such as milk, pork, beef, and chicken collectively account for nearly 40% of global agricultural GDP and generated revenues valuing nearly US$600 bn in 2015. The market for these products in developing countries is growing rapidly due to the rising population and increased disposable incomes. The resultant rise in awareness regarding the need for maintaining the excellent health of animals is expected to further drive the clostridium vaccines market in the near future.
High Consumer Dependence on Government Distribution Channels to Hamper Growth
In emerging economies, especially, government bodies play the central role in the distribution of vaccines. The Government of India, for instance, buys clostridium vaccines in bulk from manufacturers and supply them in different regions of the country. Bulk purchase of clostridium vaccines results in reduced prices, resulting in the low profitability of the market thus hampering its overall rate of development.
Moreover, the market's growth is also restrained to vast extent owing to the short exclusivity span of clostridium vaccines. Product exclusivity period in the animal health care industry is mostly only about three years to five years. Shorter exclusivity periods lead to a vast rise in competition from generics and over-the-counter (OTC) products. The increase in generic competition lowers product sales and significantly affects the profitability of the market.
This review of the market is based on a recent market research report published by Transparency Market Research, titled "Clostridium Vaccine (Animal Health) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024."
at No comments:

Interventional Radiology Market: Business Challenges, Emerging Technologies & Competitive Landscape

Global Interventional Radiology Market: Scope and Methodology
This report on the global interventional radiology market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.
The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global interventional radiology market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global Interventional Radiology market.
Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market size estimations involved in-depth study of services and product features of different types of services. Additionally, market related factors such as increasing preference for technologically advanced services, product innovation, and increasing prevalence of cancer and other chronic diseases in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.
Interventional Radiology Market: Segmentation
Based on product type, the global interventional radiology market has been segmented into x-ray, computed tomography, magnetic resonance imaging, and ultrasound. The market has been further studied from the point of view of major application. Based on application, the market has been categorized into angiography, balloon angioplasty, embolization, biopsy, vertebroplasty-Kyphoplasty, RF ablation and others. On the basis of end user, the market has been segmented hospitals, catheterization labs, ambulatory surgical centers and others.
View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/interventional-radiology-market.html
Interventional Radiology Market: Geographical and Competitive Dynamics
Geographically, the global interventional radiology market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Japan, India, Saudi Arabia, UAE, Brazil, and Mexico.
The report also profiles major players in the Interventional Radiology market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Agfa-Gevaert N.V., Fujifilm Holdings Corporation, GE Healthcare, Hitachi Medical Corporation, Hologic, Inc., Medtronic plc., Philips Healthcare, Siemens Healthineers, Teleflex Incorporated, and Toshiba Medical Systems Corporation.
at No comments:

Latex Medical Disposables Market: Latex Gloves Most Significant Contributor in terms of Revenue

Latex Medical Disposables Market: Snapshot
The global latex medical disposables market has witnessed significant growth over the last decade primarily owing to the urgent need for infection control. The demand for latex medical disposables is not just limited to super specialty hospitals but has, of late, expanded to rural hospitals and clinics.
The opportunity in the global latex medical disposables market is expected to amount to US$6.4 bn by 2024, rising from a value of US$4.1 bn in 2015 at a modest CAGR of 4.9% therein. The growth in this market can be attributed to an expanding medical tourism industry across developing countries, vigorous growth of the healthcare sector, rising focus of the government toward the medical devices market, and growing healthcare awareness among the population.
Hospitals Emerge as Leading End User of Latex Medical Disposables
By product, latex gloves emerged as the leading segment of the latex medical disposables market, accounting for a 60.4% share in terms of revenue in 2015. Latex foley catheters and latex probe covers also show significant scope for growth and the trend is likely to continue through 2024.
The key end users latex medical disposables include hospitals (private and public), ambulatory surgical centers, clinics, and diagnostic centers. Hospitals formed the dominant segment in terms of revenue in 2015, attributed to a significantly high demand. The consumption of latex medical disposables is high in hospitals because of the increased number of procedures carried out and the growing preference of patients toward public and private hospitals. The hospital segment is expected to account for a 28.7% share in 2024, closely followed by diagnostic centers.
Developing Markets of Asia Pacific and Latin America Show Immense Promise
North America leads the global latex medical disposables market and factors such as the increasing geriatric population and the introduction of new material variants by global players for the betterment of healthcare professionals can be attributed to the region’s dominance in the global market. In addition, a rise in infection control awareness has played a vital role in increasing healthcare expenditure in the region. The U.S. accounts for a major share in the North America as well as worldwide latex medical disposables market.
Europe is also a prominent contributor to the global latex medical disposables market due to a well-established healthcare network in the region. The demand for latex disposables is increasing owing to the rising number of ambulatory surgical centers as well as their growing use in home-care settings. Despite the ongoing debate about latex allergies, the size of this market is likely to expand during the course of the forecast period.
The Asia Pacific latex medical disposables market is projected to expand at the fastest CAGR during the forecast period, with China as its lead contributor. Increasing population and consumption of latex products in the country is expected to provide lucrative opportunities for global players. Moreover, a rise in the demand for other latex products such as probe covers and foley catheters in Japan and India is likely to complement the growth of the latex medical disposables market in Asia Pacific.
Players in the latex medical disposables market have been focused on strengthening their presence in Latin America due to the rising number of private hospitals in Brazil, Mexico and other countries in the region.
Key players in the latex medical disposables market include B. Braun Melsungen, Medtronic plc. (Covidien), C.R. Bard, Ansell, Hartalega Holdings Bhd., Top Glove Corporation, Supermax Corporation Berhad, and Dynarex Corporation.
at No comments:

Tissue Banking Market - Positive long-term growth outlook 2016 - 2024

Global Tissue Banking Market: Snapshot
A vast rise in the world’s geriatric population, increasing number of blood donations, rising prevalence of chronic diseases, introduction of technologically advanced equipment, favorable insurance and reimbursement policies, and rising per capita health care expenditure are the key factors driving the global tissue banking market. According to the WHO, 112.5 mn blood donations are collected on an annual basis globally. Also, the prevalence of cancer was 32.6 mn globally in 2012, and 14 mn new cases of cancer were diagnosed as compared to the previous year. Collectively, these factors are leading to an increased demand for tissue banking, which is considered to be a novel way of treating a wide range of diseases.
Transparency Market Research estimates that the global tissue banking market will exhibit a promising CAGR of 11.3% from 2016 to 2024 to reach US$ 2.1 bn by 2024.
Tissue Banking Freezers to Continue to Remain Dominant Equipment Type
Of the key variety of equipment commonly used across tissue banking facilities, the segment of freezers accounted for a significant share in the global tissue banking market in 2015. Increasing demand for regenerative medicines, cellular therapies, organ transplant, blood transfusions, and vaccines are the factors fueling the demand for freezers across the world. According to American Red Cross a total of 30 million blood components are transfused each year in the U.S. In addition, factors such as growing population, rising health care expenditure, and the rising use of a variety of tissues in the research institutes are fueling the demand for freezers in the field of tissue banking.
Freezers capable of plunging temperatures anywhere from -18°C to an ultra-low -86°C, for long-term storage of tissues are finding increased applications in the global market. The increased requirement for tissues for chronic diseases has driven the import and export of tissues globally, which is expected to fuel the market growth of storage system in the next few years. Favorable reimbursement policies are expected to support the growth of the segment in developing countries such as Brazil, China, and India.
Growth of Asia Pacific Market to Outpace Mature North America and Europe Markets
The tissue banking market in North America dominated the global tissue banking market, with a share of over 41.5% in 2015. Factors such as the rising prevalence of cancer, diabetes, cardiovascular diseases, the growing geriatric population, and technological advancements have supported the growth of the tissue banking market in the region in the past few years. Moreover, an estimated 1.6 million new cancer cases were detected in the U.S. alone in 2015. These factors collectively drive the vascular access devices market in North America. Currently in the U.S., approximately 850,000 tissue allografts are transplanted into patients annually. Much of this tissue is stored in the frozen form.
Europe ranked second in the global tissue banking market in 2015 with a 28.2% share in market’s overall revenue. Government initiatives such as the European Union Tissues and Cells Directives (EUTCD), which aim at improving awareness about safety and quality standards for human tissues and cells across the European Union, will drive Europe market in the next few years.
The tissue banking market in Asia Pacific, however, is expected to see the most promising development over the forecast period. Large population base, high target patient pool, increasing government initiatives to provide better health care facilities, rising disposable incomes, and per capita health care expenditure are driving the tissue banking market in Asia Pacific. According to Asian Diabetes Prevention initiative 60% of diabetics in the world live in Asia. By 2030, without intervention, both China and India combined will have almost half a billion diabetics. The consecutive rise in demand for regenerative medicines will provide a huge boost to the tissue banking market in the region.
Key players in the global Tissue banking market includes Thermo Fisher Scientific, Brooks Automation, Taylor-Wharton, Panasonic Biomedical, Backman Coulter Inc., Custom Biogenic Systems, Inc., Sigma-Aldrich Corporation, and BioLife Solutions, Inc.
at No comments:

Sunday, 8 January 2017

Non-Small Cell Lung Cancer Therapeutics Market Expected to Reach US$ 15.1 Bn in 2023

Non-Small Cell Lung Cancer Therapeutics Market: Snapshot
Non-small cell lung cancer (NSCLC) is the one of the commonest form of lung cancers. It is the most feared too. This is because it metastasizes into the bones and other tissues, making it tough to diagnose and treat it. In fact, almost 90% of all lung cancer cases are non-small cell lung cancer. Drugs meant to treat such a type of cancer range from regular regimens to targeted therapies. They are formulated leveraging simple chemistries to advanced complex proteins. The global market for non-small cell lung cancer therapeutics has seen robust growth due to the strong awareness among people about it. Another factor majorly contributing to the market is favorable government initiatives. Further, rapid approvals for drugs for non-small cell lung cancer by regulatory bodies and generous monetary assistance for research has also filliped the market.
Despite the efficacy of targeted therapies and the uncovering of numerous molecular targets, the development of most drugs is in an early-stage pipeline. This, coupled with resistance to targeted therapies, is a major cause of worry in the non-small cell lung cancer therapeutics market.
The global non-small cell lung cancer therapeutics market was worth US$4.9 bn in 2014. Expanding at a CAGR of 12.1% from 2015 to 2023, it is slated to achieve a value of US$15.1 bn in 2023. The global non-small cell lung cancer therapeutics market is a fragmented with robust competition among the existing players that are both generic and branded companies. Some of the prominent names operating in the market are Bristol-Myers Squibb, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Inc., AstraZeneca plc, and Novartis AG.
Burgeoning Population to Propel Market in Asia Pacific
The global market for non-small cell lung cancer therapeutics comprises five key regions: North America, Europe, Asia Pacific, and the Rest of the World. Among them, North America leads with maximum share in market on account of the presence of a superior healthcare infrastructure and strong support by the U.S. federal government. In terms of growth rate, however, Asia Pacific is predicted to outshine all other regions owing to the burgeoning population, growing awareness about non-small cell lung cancer, increasing number of government projects pertaining to lung cancer, and ongoing efforts for timely intervention.
Effectiveness of Angiogenesis Inhibitor Drives Growth
The global market for non-small cell lung cancer therapeutics market can be segmented on the basis of drugs into EGFR inhibitor, angiogenesis inhibitor, microtubule stabilizer, kinase inhibitor, folate antimetabolites, and PD-1/PD-L1 inhibitor. At present angiogenesis inhibitor, also known as anti-angiogenics that thwart formation of new blood vessels, dominates the market. Going forward too, it is likely to retain its leading position because of the strong demand for this efficacious, targeted therapy in the crucial Europe, Japan, and the U.S. markets. Avastin, a type of angiogenesis inhibitor, is predicted to see maximum uptake. Exhibiting a CAGR of 1.8% from 2015 to 2023, the angiogenesis inhibitor segment is predicted to attain a market value of US$ 2,020.4 mn by 2023.
The folate antimetabolites segment trails the angiogenesis inhibitor segment in the global non-small cell lung cancer therapeutics market. The EGFR inhibitor and microtubule stabilizer segments come in third and fourth positions in terms of market share. The PD-1/PD-L1 inhibitor will likely outpace all other segments vis-à-vis growth in the upcoming years due to the effectiveness of the treatment, which has been corroborated by clinical data that shows double survival rate. Unveiling of new targeted therapies with more surveillance rate could, however, hobble the growth in the market.
at No comments:

Thursday, 5 January 2017

Intracranial Pressure Monitors Market expected to expand at a CAGR of 6.30% during the period from 2015 to 2023

Traumatic brain injuries and strokes remain one of the leading causes of death and disability across the globe. The upswing in the cases of brain injuries in adults as well as children has proved to be a shot in the arm for the global intracranial pressure monitors market. The Centers for Disease Control and Prevention states that every day nearly 140 people in the U.S. die from injuries that are associated with traumatic brain injuries.
According to a report by Transparency Market Research (TMR), the opportunity in the global intracranial pressure monitors market was pegged at US$0.94 bn in 2014 and is poised to reach US$1.63 bn by 2023, rising at a CAGR of 6.30% between 2015 and 2023. A TMR analyst states that the sweeping shift towards non-invasive pressure monitors from invasive ones is likely to have a positive and enduring impact on the dynamics of the market.
How are governments playing an important role in the growth of the global intracranial pressure monitors market?
Governments across the world are raising their budgets for the healthcare development. For instance, the Centers for Medicare and Medicaid Services revealed that the U.S. government had increased the bar for healthcare spending from 3.6% in 2013 to 5% in 2014. Other developed countries such as France, Japan, and Germany are also increasing their healthcare spending every year. France’s healthcare system covers the public-private mix of hospital and ambulatory care with a higher volume of service provisions as compared to the U.S. Emerging countries such as India, China, and the Philippines are also jumping on the bandwagon, thereby providing a boost to the overall intracranial pressure monitors market.
How are developed regions contributing to the growth of the global intracranial pressure monitors market?
North America will continue to dominate the market in terms of revenue until 2023, followed by Europe. The rising incidence of traumatic injuries and neurological disorders are boosting the demand for intracranial pressure monitors in these regions. In addition, the rapid technological advancements in the field of pressure monitoring are anticipated to provide a fillip to these regional markets as well as the global market.
Why are manufacturers in the global intracranial pressure monitors market shifting focus towards emerging markets?
Despite the dominance of North America, Asia Pacific will offer substantial lucrative opportunities to market players, owing to the presence of numerous untapped markets. Over the past few years, the cases of cerebrovascular disorders have recorded a sudden rise, primarily due to the growing aging population in this region. Moreover, the consumer expenditure on healthcare has increased, thanks to the rising disposable income. Owing to these factors, the Asia Pacific market for intracranial pressure monitors is estimated to expand at a significant CAGR during the forecast period.
at No comments:

Demand for Anti-snoring Devices and Snoring Surgery Market will be Proportional to the Increase in Snoring Cases Diagnosed Worldwide

The leading companies operating in the anti-snoring devices and snoring surgery market have been focusing on product innovation and miniaturization of sleep apnea devices. This is a novel trend swaying the global anti-snoring devices and snoring surgery market. Integrated by the nanotechnology, this trend could be a major determinant for the market’s growth. Currently, the market is exhibiting a strong focus on innovation, as per a new study by Transparency Market Research. Efforts by new and existing players have resulted in the development of an impressive pipeline of products that are expected to help find better cure for people suffering from sleep apnea.
Q: What strategies are the leading market players adopting to gain stronghold?
A: The global anti-snoring devices and snoring surgery market is marked by the presence of an increasing number of companies which has rendered its vendor landscape highly competitive and fragmented. TMR finds that enterprises such as Medtronic plc, Philips Healthcare, GE Healthcare, Fisher & Paykel Healthcare, and ResMed, Inc are not only leading market participant but also hold significant share in the global market with their robust geographic reach and extensive product portfolio.
Of these, Medtronic has managed emerging dominant in the overall market following a slew of recent acquisitions. Medtronic along with Phillips Healthcare and GE healthcare are the top players in the market, contributing a whopping 93.69% of the overall revenue generated by the market. In order to accelerate their pace of gains, a majority of the leading companies operating in the anti-snoring devices and snoring surgery market are investing in research and development activities.
Besides this they are also focusing on product innovation to strengthen their position in the market. For instance, an Australian company has recently launched a 3D printed anti-snoring device that can be customized based on an individual’s need. The medical device company is called Oventus Medical and is based in Melbourne, Australia. It is set to manufacture a device they named O2Vent. It is a lightweight titanium devices and can help patients stop snoring by delivering air to the back of his or her mouth. Such innovations hold great promise of the company success in the market
Q: Which region will offer most lucrative opportunities to the market?
A: North America and Europe together dominated the global anti-soring devices and snoring surgery market in 2015. While these are mature markets, the opportunities existing in Asia Pacific is also expected to prove quite lucrative for companies manufacturing anti-snoring devices. Because the region is characterized by presence of unmet medical needs and high patient pool it is expected to attract several of the small or medium scale companies and new entrants looking to establish their footprint in the market. In addition favorable government initiatives to spread awareness about sleep apnea and its possible treatments will also support the market’s strong growth in Asia Pacific.
at No comments:

Medical Lifting Slings Market is expected to rise at a CAGR of 9.2% between 2016 and 2024

Although the medical lifting slings market exhibits fragmentation in developing countries, global giants such as Invacare Corporation, Bestcare, LLC, GF Health Products, Inc., Etac AB, DJO Global, ArjoHuntleigh, Joerns Healthcare, LLC, Argo Medical, Inc., Prism Medical, and Drive DeVilbiss Healthcare have cemented significant and consolidated presence in developed markets, says a report by Transparency Market Research (TMR).
According to the report, the global market is anticipated to rise at a CAGR of 9.2% from US$391.8 mn recorded in 2015 to US$910.6 mn by the end of 2024.
Major players in the medical lifting slings market are looking forward to broaden their services base across different geographical regions, especially those incorporating emerging nations. Argo Medical, Inc., for instance, offers a fleet of equipment maintenance and customized healthcare services to attract the attention of customers.
The augmenting trend of privatization in the healthcare sector and far-reaching awareness about mobility aids are predicted to draw the interest of businesses and investors in the global market. Besides this, inflating number of government and private insurance products will add to the growth of the market.
Asia Pacific to Achieve Speedy Growth throughout the Forecast Period
On the basis of sling point, the international medical lifting slings market is foreseen to be dominated by the 4 point sling segment until 2024 with a whopping percentage share while rising to US$400.6 mn by 2024 from US$168.8 mn in 2015. Other segments discussed on the same parameter are 2 point sling and 6 point sling.
Although Europe is envisaged to take grip of a mammoth share of the global medical lifting slings market for the forecast period at an 8.9% CAGR, Asia Pacific (APAC) will be the leading segment by geography in terms of growth rate. The transfer sling and universal sling product type segments and 4 point sling segment will significantly contribute to the growth of the APAC market.
New companies will have little hopes to enter the worldwide medical lifting slings market, although the demand for economical, technologically sophisticated, and adaptable products may attract them. Shortened product lifecycle, market consolidation, increasing research and development expenses, and price competition are the constraints of the growth of new entrants.
The bargaining power of suppliers is expected to be low with the rising risk of forward integration and demand for mobility merchandise. Moreover, the number of raw material and equipment suppliers prevailing in the market is enormous with a broad scope of slings and related accessories available for purchase.
Increasing Geriatric Population to Push Global Market
The provision of offering medical lifting slings on rental basis in home care settings has inclined the global market towards growth. Government and private organizations in emerging regions have targeted low income group patients by providing them rental care services. Furthermore, there are multiple number of programs initiated to help the poverty-stricken patients bear the expense of the purchase and maintenance of slings.
Favorable initiatives by government organizations such as the Occupational Safety and Health Administration (OSHA) are promoting the usage of slings to avoid injuries and musculoskeletal disorders (MSDs).
With almost 50% of the global geriatric population accounted by APAC to expand strikingly by 2020 according to the United Nations (UN), the international medical lifting slings market is expected to see a rise. Global population aged 65 years and above is envisioned to reach 2.0 bn by 2050, as per the statistics of the World Health Organization (WHO).
Lack of Technical Knowledge and Training Could Influence Growth
Lack of proper training and amateur technical know-how on the part of end-users, such as hospital staffs, could hamper the advancement of the medical lifting slings market, especially in the emerging economies. However, most end-users are now focusing on delivering apposite information and sufficient training related to patient handling and moving. This is expected to compensate for the effect of the market constraints.
The information presented in this review is based on a Transparency Market Research report titled “Medical Lifting Slings Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016–2024.”
at No comments:

Monday, 2 January 2017

Hematological Malignancies Market: Growing Prevalence of Leukemia to Support Demand for Therapeutics, says TMR

With the presence of a few but prominent players, such as Celgene, Roche, Novartis, and AbbVie, the global hematological malignancies market demonstrates an intensely competitive landscape. These four players collectively accounted for more than 58% of the overall market in 2015. Currently, they are focusing aggressively on expanding their distribution networks and geographical operations across Asia Pacific, Latin America, and the Middle East and Africa. Researchers expect the leading companies in this market to engage in mergers and acquisitions over the forthcoming years in a bid to bring about product differentiation to combat the competition.
As per the report, the global market for hematological malignancies offered an opportunity worth US$27.4 bn in 2015. Rising at a 7.50% CAGR between 2016 and 2024, this market is likely to increase to US$51.9 bn by the end of the forecast period. The prevalence of leukemia has been higher than lymphoma and myeloma. The trend is expected to remain so with the leukemia segment occupying nearly 50% of the overall market for hematological malignancies by 2024.
North America to Continue to Lead Global Hematological Malignancies Market
A regional analysis of the worldwide market for hematological malignancies has also been offered in this research report. According to the study, North America, the Middle East and Africa, Latin America, Europe, and Asia Pacific are the main regional markets for hematological malignancies across the world. In 2015, North America acquired the leading position in this market and was closely followed by Europe. The high prevalence of hematological cancers, together with state-of-art diagnostic technologies and increased awareness level of people, propelled the hematological malignancies significantly in both the regions.
Progressing at a CAGR of 6.80%, North America is likely to retain its leadership over the forecast period. The presence of an advanced healthcare infrastructure is likely to support this regional market to register a steady rise in the near future. Apart from this, the Asia Pacific market for hematological malignancies is also projected to witness strong growth over the next few years, owing to the existing rich pipeline and the imminent launch of targeted therapies during the forecast period, states the research report.
Technological Advancements in Diagnostic Procedures to Positively Impact Demand
The sedentary and unhealthy lifestyle of people across the world has exposed them to a number of lifestyle-related diseases, hematological malignancies being a prominent one of them. The National Cancer Institute has stated that hematological cancer is the fifth most common cancer among people, globally, and is likely to record increased prevalence over the next few years. “With the upswing in the cases of hematological malignancies, the demand for their treatment is registering a tremendous rise, leading to a remarkable surge in the global market for hematological malignancies,” says an analyst at TMR.
In addition to this, the technological advancements in diagnostic procedures and the growing awareness level are projected to encourage people to go for diagnostic tests, which is likely to influence this market substantially in the near future. However, high costs of branded drugs and the absence of favorable reimbursement policies in emerging nations may hamper this market from growing steadily in the years to come, notes the study.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”
at No comments:

Clostridium Vaccine (Animal Health) Market: Bovine Segment to Bring in Significant Percentage of Sales

The global clostridium vaccine (animal health) market features a largely consolidated competitive landscape, with the top five companies collectively accounting for a share of over 63% of the overall market in 2015, observes a recent report by Transparency Market Research (TMR). These top vendors, namely Zoetis, Inc., Merck & Co., Sanofi-Aventis, Boehringer Ingelheim, and Eli Lilly and Company hold commanding positions owing to their wide geographic presence and a strong financial backing allowing increased focus on research and development activities.
Top companies in the market aim to strengthen their positions with strategies such as targeted in-licensing, acquisition, and innovative marketing. Use of the digital medium to reach out to an extended consumer base and serve the consumer more effectively has also started becoming a popular strategy. An instance is the recent update made to Bayer’s BCS cowdition smartphone application in July 2016. The enhanced application is expected to help veterinarians to track the current and future hurdles regarding cattle health, which will help minimize the impact of metabolic diseases on dairy cows.
Transparency Market Research estimates that the global clostridium vaccines market will exhibit a healthy 4.9% CAGR over the period between 2016 and 2024. Rising at this rate, the market, which valued at US$418.0 mn in 2015, is expected to reach US$643.5 mn by 2024. In terms of animal species, the swine segment presently leads but is expected to be outpaced by the growth of the ovine segment. In terms of geography, the global market is dominated by North America, which accounted for over 37% of the global market in 2015.
Rising Intervention by Government Bodies to Play Key Role in Market Development
Government initiatives play a key role the development of animal health care markets. For instance, the China market for veterinary healthcare is chiefly driven by compulsory immunization policy, several animal health awareness programs, the easy availability of affordable veterinary vaccines, and fund for research and development in the field. In several other developed as well as developing economies, funds invested by government bodies for the research and development of veterinary vaccines and medications play a key role in boosting the demand for clostridium vaccines.
Along with this, the rising global demand for animal products such as cattle milk, meat, and eggs is also a key factor driving the global market for clostridium vaccines. Animal products such as milk, pork, beef, and chicken collectively account for nearly 40% of global agricultural GDP and generated revenues valuing nearly US$600 bn in 2015. The market for these products in developing countries is growing rapidly due to the rising population and increased disposable incomes. The resultant rise in awareness regarding the need for maintaining the excellent health of animals is expected to further drive the clostridium vaccines market in the near future.
High Consumer Dependence on Government Distribution Channels to Hamper Growth
In emerging economies, especially, government bodies play the central role in the distribution of vaccines. The Government of India, for instance, buys clostridium vaccines in bulk from manufacturers and supply them in different regions of the country. Bulk purchase of clostridium vaccines results in reduced prices, resulting in the low profitability of the market thus hampering its overall rate of development.
Moreover, the market's growth is also restrained to vast extent owing to the short exclusivity span of clostridium vaccines. Product exclusivity period in the animal health care industry is mostly only about three years to five years. Shorter exclusivity periods lead to a vast rise in competition from generics and over-the-counter (OTC) products. The increase in generic competition lowers product sales and significantly affects the profitability of the market.
This review of the market is based on a recent market research report published by Transparency Market Research, titled "Clostridium Vaccine (Animal Health) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024."
at No comments: